U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H22O3
Molecular Weight 310.3869
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AVOBENZONE

SMILES

COC1=CC=C(C=C1)C(=O)CC(=O)C2=CC=C(C=C2)C(C)(C)C

InChI

InChIKey=XNEFYCZVKIDDMS-UHFFFAOYSA-N
InChI=1S/C20H22O3/c1-20(2,3)16-9-5-14(6-10-16)18(21)13-19(22)15-7-11-17(23-4)12-8-15/h5-12H,13H2,1-4H3

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including: http://www.wikidoc.org/index.php/Avobenzone | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de3fd7fb-4a28-4db8-9a4d-d7fdd2e45daf

Avobenzone is an oil soluble ingredient used in sunscreen products to absorb the full spectrum of UVA rays. It helps prevent sunburn. Avobenzone works by absorbing the rays and converting them to energy that is less damaging to the skin.

Originator

Approval Year

1988
90
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Approved
8583
SHADE UVAGUARD

Approved Use

helps prevent sunburn; higher SPF gives more sunburn protection; helps provide protection from UVA rays (short and long wavelengths).

Launch Date

1992
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7.1 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/31058986/
832.5 mg 4 times / day multiple, topical
dose: 832.5 mg
route of administration: Topical
experiment type: MULTIPLE
co-administered: OCTOCRYLENE
OCTOCRYLENE
 AVOBENZONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3.5 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/31058986/
810 mg 4 times / day multiple, topical
dose: 810 mg
route of administration: Topical
experiment type: MULTIPLE
co-administered: OXYBENZONE
OXYBENZONE
 AVOBENZONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3.4 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/31058986
810 mg 4 times / day multiple, topical
dose: 810 mg
route of administration: Topical
experiment type: MULTIPLE
co-administered: OXYBENZONE
OXYBENZONE
 AVOBENZONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1.8 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/31058986
576 mg 4 times / day multiple, topical
dose: 576 mg
route of administration: Topical
experiment type: MULTIPLE
co-administered: OCTOCRYLENE
OCTOCRYLENE
 AVOBENZONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
591.2 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/31058986/
832.5 mg 4 times / day multiple, topical
dose: 832.5 mg
route of administration: Topical
experiment type: MULTIPLE
co-administered: OCTOCRYLENE
OCTOCRYLENE
 AVOBENZONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
350.1 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/31058986/
810 mg 4 times / day multiple, topical
dose: 810 mg
route of administration: Topical
experiment type: MULTIPLE
co-administered: OXYBENZONE
OXYBENZONE
 AVOBENZONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
112.3 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/31058986/
832.5 mg 4 times / day multiple, topical
dose: 832.5 mg
route of administration: Topical
experiment type: MULTIPLE
co-administered: OCTOCRYLENE
OCTOCRYLENE
 AVOBENZONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
94.2 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/31058986/
810 mg 4 times / day multiple, topical
dose: 810 mg
route of administration: Topical
experiment type: MULTIPLE
co-administered: OXYBENZONE
OXYBENZONE
 AVOBENZONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
45.2 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/31058986
810 mg 4 times / day multiple, topical
dose: 810 mg
route of administration: Topical
experiment type: MULTIPLE
co-administered: OXYBENZONE
OXYBENZONE
 AVOBENZONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
33 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/31058986
576 mg 4 times / day multiple, topical
dose: 576 mg
route of administration: Topical
experiment type: MULTIPLE
co-administered: OCTOCRYLENE
OCTOCRYLENE
 AVOBENZONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
3.7 g 1.3 times / day multiple, topical
Recommended
Dose: 3.7 g, 1.3 times / day
Route: topical
Route: multiple
Dose: 3.7 g, 1.3 times / day
Sources:
https://www.fda.gov/media/71361/download
healthy, 3.69 years (range: 0.64-48.15 years)
Health Status: healthy
Age Group: 3.69 years (range: 0.64-48.15 years)
Sex: M+F
Sources:
https://www.fda.gov/media/71361/download
Other AEs: Dermatitis, Eczema...
Other AEs:
Dermatitis (2.5%)
Eczema (1.3%)
Sources:
https://www.fda.gov/media/71361/download
1.6 g 1.1 times / day multiple, topical
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Sources:
https://www.fda.gov/media/71361/download
healthy, 35.44 years (range: 12.04-83.43 years)
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Sources:
https://www.fda.gov/media/71361/download
Other AEs: Acne, Dermatitis...
Other AEs:
Acne (4.8%)
Dermatitis (2.8%)
Dry skin (1.2%)
Eczema (1.2%)
Erythema (1.2%)
Pruritus (2%)
Rosacea (0.4%)
Seborrhea (0.8%)
Skin discomfort (1.2%)
Sunburn (0.8%)
Conjunctivitis (0.8%)
Taste perversion (0.4%)
Sources:
https://www.fda.gov/media/71361/download
3.1 g 1.2 times / day multiple, topical
Recommended
Dose: 3.1 g, 1.2 times / day
Route: topical
Route: multiple
Dose: 3.1 g, 1.2 times / day
Sources:
https://www.fda.gov/media/71361/download
healthy, 6.69 years (range: 0.5-67.95 years)
Health Status: healthy
Age Group: 6.69 years (range: 0.5-67.95 years)
Sex: M+F
Sources:
https://www.fda.gov/media/71361/download
Other AEs: Dermatitis, Eczema...
Other AEs:
Dermatitis (2.8%)
Eczema (0.4%)
Erythema (0.8%)
Skin discomfort (0.8%)
Sunburn (1.6%)
Conjunctivitis (0.4%)
Sources:
https://www.fda.gov/media/71361/download
AEs

AEs

AESignificanceDosePopulation
Eczema 1.3%
3.7 g 1.3 times / day multiple, topical
Recommended
Dose: 3.7 g, 1.3 times / day
Route: topical
Route: multiple
Dose: 3.7 g, 1.3 times / day
Sources:
https://www.fda.gov/media/71361/download
healthy, 3.69 years (range: 0.64-48.15 years)
Health Status: healthy
Age Group: 3.69 years (range: 0.64-48.15 years)
Sex: M+F
Sources:
https://www.fda.gov/media/71361/download
Dermatitis 2.5%
3.7 g 1.3 times / day multiple, topical
Recommended
Dose: 3.7 g, 1.3 times / day
Route: topical
Route: multiple
Dose: 3.7 g, 1.3 times / day
Sources:
https://www.fda.gov/media/71361/download
healthy, 3.69 years (range: 0.64-48.15 years)
Health Status: healthy
Age Group: 3.69 years (range: 0.64-48.15 years)
Sex: M+F
Sources:
https://www.fda.gov/media/71361/download
Rosacea 0.4%
1.6 g 1.1 times / day multiple, topical
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Sources:
https://www.fda.gov/media/71361/download
healthy, 35.44 years (range: 12.04-83.43 years)
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Sources:
https://www.fda.gov/media/71361/download
Taste perversion 0.4%
1.6 g 1.1 times / day multiple, topical
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Sources:
https://www.fda.gov/media/71361/download
healthy, 35.44 years (range: 12.04-83.43 years)
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Sources:
https://www.fda.gov/media/71361/download
Conjunctivitis 0.8%
1.6 g 1.1 times / day multiple, topical
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Sources:
https://www.fda.gov/media/71361/download
healthy, 35.44 years (range: 12.04-83.43 years)
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Sources:
https://www.fda.gov/media/71361/download
Seborrhea 0.8%
1.6 g 1.1 times / day multiple, topical
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Sources:
https://www.fda.gov/media/71361/download
healthy, 35.44 years (range: 12.04-83.43 years)
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Sources:
https://www.fda.gov/media/71361/download
Sunburn 0.8%
1.6 g 1.1 times / day multiple, topical
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Sources:
https://www.fda.gov/media/71361/download
healthy, 35.44 years (range: 12.04-83.43 years)
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Sources:
https://www.fda.gov/media/71361/download
Dry skin 1.2%
1.6 g 1.1 times / day multiple, topical
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Sources:
https://www.fda.gov/media/71361/download
healthy, 35.44 years (range: 12.04-83.43 years)
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Sources:
https://www.fda.gov/media/71361/download
Eczema 1.2%
1.6 g 1.1 times / day multiple, topical
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Sources:
https://www.fda.gov/media/71361/download
healthy, 35.44 years (range: 12.04-83.43 years)
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Sources:
https://www.fda.gov/media/71361/download
Erythema 1.2%
1.6 g 1.1 times / day multiple, topical
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Sources:
https://www.fda.gov/media/71361/download
healthy, 35.44 years (range: 12.04-83.43 years)
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Sources:
https://www.fda.gov/media/71361/download
Skin discomfort 1.2%
1.6 g 1.1 times / day multiple, topical
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Sources:
https://www.fda.gov/media/71361/download
healthy, 35.44 years (range: 12.04-83.43 years)
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Sources:
https://www.fda.gov/media/71361/download
Pruritus 2%
1.6 g 1.1 times / day multiple, topical
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Sources:
https://www.fda.gov/media/71361/download
healthy, 35.44 years (range: 12.04-83.43 years)
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Sources:
https://www.fda.gov/media/71361/download
Dermatitis 2.8%
1.6 g 1.1 times / day multiple, topical
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Sources:
https://www.fda.gov/media/71361/download
healthy, 35.44 years (range: 12.04-83.43 years)
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Sources:
https://www.fda.gov/media/71361/download
Acne 4.8%
1.6 g 1.1 times / day multiple, topical
Recommended
Dose: 1.6 g, 1.1 times / day
Route: topical
Route: multiple
Dose: 1.6 g, 1.1 times / day
Sources:
https://www.fda.gov/media/71361/download
healthy, 35.44 years (range: 12.04-83.43 years)
Health Status: healthy
Age Group: 35.44 years (range: 12.04-83.43 years)
Sex: M+F
Sources:
https://www.fda.gov/media/71361/download
Conjunctivitis 0.4%
3.1 g 1.2 times / day multiple, topical
Recommended
Dose: 3.1 g, 1.2 times / day
Route: topical
Route: multiple
Dose: 3.1 g, 1.2 times / day
Sources:
https://www.fda.gov/media/71361/download
healthy, 6.69 years (range: 0.5-67.95 years)
Health Status: healthy
Age Group: 6.69 years (range: 0.5-67.95 years)
Sex: M+F
Sources:
https://www.fda.gov/media/71361/download
Eczema 0.4%
3.1 g 1.2 times / day multiple, topical
Recommended
Dose: 3.1 g, 1.2 times / day
Route: topical
Route: multiple
Dose: 3.1 g, 1.2 times / day
Sources:
https://www.fda.gov/media/71361/download
healthy, 6.69 years (range: 0.5-67.95 years)
Health Status: healthy
Age Group: 6.69 years (range: 0.5-67.95 years)
Sex: M+F
Sources:
https://www.fda.gov/media/71361/download
Erythema 0.8%
3.1 g 1.2 times / day multiple, topical
Recommended
Dose: 3.1 g, 1.2 times / day
Route: topical
Route: multiple
Dose: 3.1 g, 1.2 times / day
Sources:
https://www.fda.gov/media/71361/download
healthy, 6.69 years (range: 0.5-67.95 years)
Health Status: healthy
Age Group: 6.69 years (range: 0.5-67.95 years)
Sex: M+F
Sources:
https://www.fda.gov/media/71361/download
Skin discomfort 0.8%
3.1 g 1.2 times / day multiple, topical
Recommended
Dose: 3.1 g, 1.2 times / day
Route: topical
Route: multiple
Dose: 3.1 g, 1.2 times / day
Sources:
https://www.fda.gov/media/71361/download
healthy, 6.69 years (range: 0.5-67.95 years)
Health Status: healthy
Age Group: 6.69 years (range: 0.5-67.95 years)
Sex: M+F
Sources:
https://www.fda.gov/media/71361/download
Sunburn 1.6%
3.1 g 1.2 times / day multiple, topical
Recommended
Dose: 3.1 g, 1.2 times / day
Route: topical
Route: multiple
Dose: 3.1 g, 1.2 times / day
Sources:
https://www.fda.gov/media/71361/download
healthy, 6.69 years (range: 0.5-67.95 years)
Health Status: healthy
Age Group: 6.69 years (range: 0.5-67.95 years)
Sex: M+F
Sources:
https://www.fda.gov/media/71361/download
Dermatitis 2.8%
3.1 g 1.2 times / day multiple, topical
Recommended
Dose: 3.1 g, 1.2 times / day
Route: topical
Route: multiple
Dose: 3.1 g, 1.2 times / day
Sources:
https://www.fda.gov/media/71361/download
healthy, 6.69 years (range: 0.5-67.95 years)
Health Status: healthy
Age Group: 6.69 years (range: 0.5-67.95 years)
Sex: M+F
Sources:
https://www.fda.gov/media/71361/download
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
2252
inhibitor
2438
inhibitor
2507

OverviewOther

Other InhibitorOther SubstrateOther Inducer
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP2C9
2497
 no
CYP2D6
2546
 no
CYP3A4
2633
 no
Sourcing

Sourcing

Vendor/AggregatorIDURL
3B Scientific (Wuhan) Corp
3B5-01495
http://www.3bsc.com/index/pro_info.php?id=69114
AA Blocks
AA00342H
http://www.aablocks.com/goods/Goods/detail?id=AA00342H
Aaron Chemicals
AR0034U9
http://www.aaronchem.com/70356-09-1
abcr GmbH
AB261323
http://www.abcr.com/shop/en/AB261323
AbMole Bioscience
M5434
http://www.abmole.com/products/avobenzone.html
Acadechem
ACDS-036868
http://www.acadechemical.com/product/111567
Achemica
ACMC-209oe7
http://www.achemica.com/prodinfo/?id=130770
Achemtek
0104-012933
http://www.achemtek.com/70356-09-1
Acorn PharmaTech
ACN-S002307
http://www.acornpharmatech.com/
AK Scientific, Inc. (AKSCI)
71158
http://www.aksci.com/item_detail.php?cat=71158
Angene
AGN-PC-0JKY2S
http://www.angenechemical.com/productshow/AGN-PC-0JKY2S.html
Anward
ANW-35885
http://www.anward.com/pro_result/1413
ApexBio Technology
B2079
http://www.apexbt.com/avobenzone.html
Ark Pharm
AK-48454
http://www.arkpharminc.com/products/70356-09-1.html
Aromsyn
AS04672
http://www.aromsyn.com/product/AS04672.html
Aurora Fine Chemicals LLC
A17.901.658
http://online.aurorafinechemicals.com/info?ID=A17.901.658
Avantor Inc
700004-106
https://us.vwr.com/store/product/21572552/1-4-tert-butylphenyl-3-4-methoxyphenyl-1-3-propanedione
Avantor Inc
700004-108
https://us.vwr.com/store/product/21572552/1-4-tert-butylphenyl-3-4-methoxyphenyl-1-3-propanedione
Avantor Inc
700004-110
https://us.vwr.com/store/product/21572552/1-4-tert-butylphenyl-3-4-methoxyphenyl-1-3-propanedione
BioCrick
BCC4891
http://www.biocrick.com/Avobenzone-BCC4891.html
BioSynth
Q-200661
https://www.biosynth.com/en/products/life-science/other-biochemicals/products/Q-200661.html
BLD Pharm
BD51410
http://www.bldpharm.com/products/70356-09-1.html
Boerchem
BC215936
http://www.boerchem.com/?product_36612.html
Chem Scene
CS-2356
http://www.chemscene.com/70356-09-1.html
ChemMol
30107627
http://www.chemmol.com/chemmol/30107627.html
ChemMol
44005429
http://www.chemmol.com/chemmol/44005429.html
ChemMol
49408542
http://www.chemmol.com/chemmol/49408542.html
ChemMol
99160632
http://www.chemmol.com/chemmol/99160632.html
Chemspace
CSSB00016988247
https://chem-space.com/CSSB00016988247
Clearsynth
CS-O-10849
https://www.clearsynth.com/en/CSO10849.html
DC Chemicals
DCAPI1313
http://www.dcchemicals.com//product_show-Avobenzone_Parsol_1789_.html
eNovation Chemicals
D669289
https://www.enovationchem.com/ProductDetails.asp?ProductID=D669289
Finetech
FT-0623334
http://www.finetechnology-ind.com/prod/detail/pub/70356-09-1.html
Hairui
HR129959
http://www.hairuichem.com/en/product/70356-09-1.html
iChemical
EBD34539
http://www.ichemical.com/products/70356-09-1.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
Lab Network
LN00193793
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00193793
LGC Standards
DRE-C15894520
https://www.lgcstandards.com/US/en/p/DRE-C15894520
LGC Standards
LGCFOR0902.00
https://www.lgcstandards.com/US/en/p/LGCFOR0902.00
MedChem Express
HY-B0316
https://www.medchemexpress.com/Avobenzone.html
MuseChem
A000883
https://www.musechem.com/product/A000883.html
Parchem
25912
http://www.parchem.com/chemical-supplier-distributor/Avobenzone-015912.aspx
Renno Tech
RL04694
http://www.rennotech.com/product_show.asp?id=4943
Sigma-Aldrich
1045337_USP
https://www.sigmaaldrich.com/catalog/product/usp/1045337?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
16633_SIAL
https://www.sigmaaldrich.com/catalog/product/sial/16633?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
PHR1073_SIAL
https://www.sigmaaldrich.com/catalog/product/sial/phr1073?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech
S021211
http://www.sinfoobiotech.com/product/1024609
Smolecule
S519867
http://www.smolecule.com/products/s519867
TCI (Tokyo Chemical Industry)
B3382
http://www.tcichemicals.com/eshop/en/us/commodity/B3382/index.html
THE BioTek
bt-261258
https://www.thebiotek.com/product/inhibitors/bt-261258
VladaChem
VL273859-100G
https://www.vladachem.com/product.php?products=70356-09-1
Yuhao Chemical
LT1520
http://www.chemyuhao.com/70356-09-1.html
PubMed

PubMed

TitleDatePubMed
Chemical allergens stimulate human epidermal keratinocytes to produce lymphangiogenic vascular endothelial growth factor.
2015-03-01
FDA-approved drugs and other compounds tested as inhibitors of human glutathione transferase P1-1.
2013-09-05
Characterization of the UVA protection provided by avobenzone, zinc oxide, and titanium dioxide in broad-spectrum sunscreen products.
2010-12-01
True photoallergy to sunscreens is rare despite popular belief.
2010-07-22
An Assessment of the Efficacy and Safety of CROSS Technique with 100% TCA in the Management of Ice Pick Acne Scars.
2010-05
Determination of organic UV filters in water by stir bar sorptive extraction and direct analysis in real-time mass spectrometry.
2010-05
Filter-filter interactions. Photostabilization, triplet quenching and reactivity with singlet oxygen.
2010-04
A randomized, controlled comparative study of the wrinkle reduction benefits of a cosmetic niacinamide/peptide/retinyl propionate product regimen vs. a prescription 0.02% tretinoin product regimen.
2010-03
Polymorphism and reversible mechanochromic luminescence for solid-state difluoroboron avobenzone.
2010-02-24
Optical and electron paramagnetic resonance studies of the excited states of 4-tert-butyl-4'-methoxydibenzoylmethane and 4-tert-butyl-4'-methoxydibenzoylpropane.
2009-12-03
Photodegradation of dibenzoylmethanes: potential cause of photocontact allergy to sunscreens.
2009-11
Evaluation of spray congealing as technique for the preparation of highly loaded solid lipid microparticles containing the sunscreen agent, avobenzone.
2009-08
Addressing technical challenges associated with the FDA's proposed rules for the UVA in vitro testing procedure.
2009-06-15
A new ecamsule-containing SPF 40 sunscreen cream for the prevention of polymorphous light eruption: a double-blind, randomized, controlled study in maximized outdoor conditions.
2009-02
Impact on facial rejuvenation with dermatological preparations.
2009
Role of UV light in photodamage, skin aging, and skin cancer: importance of photoprotection.
2009
In vitro assessments of UVA protection by popular sunscreens available in the United States.
2008-12
A blocked diketo form of avobenzone: photostability, photosensitizing properties and triplet quenching by a triazine-derived UVB-filter.
2008-08-05
Influence of hydroxypropyl-beta-cyclodextrin on transdermal penetration and photostability of avobenzone.
2008-06
Assessing retinol stability in a hydroquinone 4%/retinol 0.3% cream in the presence of antioxidants and sunscreen under simulated-use conditions: a pilot study.
2008-03
Photostability and efficacy studies of topical formulations containing UV-filters combination and vitamins A, C and E.
2007-10-01
Degradation kinetics of butylmethoxydibenzoylmethane (avobenzone) in aqueous solution.
2007-10
Mexoryl: a review of an ultraviolet a filter.
2007-09-15
OTC product: Anthelios SX.
2007-09-13
I've heard there's a new sunscreen that's supposed to offer better skin protection. Can you tell me more?
2007-06
A new sunscreen agent.
2007-05-21
The FDA approves new over-the-counter sunscreen.
2007-03-01
[Simultaneous determination of 9 ultraviolet absorbers in cosmetics by high-performance liquid chromatography].
2007
Transient enol isomers of dibenzoylmethane and avobenzone as efficient hydrogen donors toward a nitroxide pre-fluorescent probe.
2006-11-11
Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods.
2006-11
Interactions between different solar UVB/UVA filters contained in commercial suncreams and consequent loss of UV protection.
2006-09
Sun protection strength of a hydroquinone 4%/retinol 0.3% preparation containing sunscreens.
2006-04
Changes in ultraviolet absorbance and hence in protective efficacy against lipid peroxidation of organic sunscreens after UVA irradiation.
2006-03-01
Design of a photostabilizer having built-in antioxidant functionality and its utility in obtaining broad-spectrum sunscreen formulations.
2006-02-24
Evaluation of the photostability of different UV filter combinations in a sunscreen.
2006-01-13
A new long-chain UV absorber derived from 4-tert-butyl-4'-methoxydibenzoylmethane: absorbance stability under solar irradiation.
2005-02-16
Interaction of polycyclic musks and UV filters with the estrogen receptor (ER), androgen receptor (AR), and progesterone receptor (PR) in reporter gene bioassays.
2005-02
Unexpected photolysis of the sunscreen octinoxate in the presence of the sunscreen avobenzone.
2004-11-25
Lack of in vitro protection by a common sunscreen ingredient on UVA-induced cytotoxicity in keratinocytes.
2004-10-15
Sunscreen penetration of human skin and related keratinocyte toxicity after topical application.
2004-09-28
Determination of sixteen UV filters in suncare formulations by high-performance liquid chromatography.
2004-09-17
Photochemical behavior of a new long-chain UV absorber derived from 4-tert-butyl-4'-methoxydibenzoylmethane.
2004-09-15
Non-invasive in vivo determination of UVA efficacy of sunscreens using diffuse reflectance spectroscopy.
2003-08
Bioconvertible vitamin antioxidants improve sunscreen photoprotection against UV-induced reactive oxygen species.
2003-05-20
Protection against UVB irradiation by natural filters extracted from lichens.
2002-11
The effects of derivatives of the nitroxide tempol on UVA-mediated in vitro lipid and protein oxidation.
2002-07-01
The effect of UV absorbing sunscreens on the reflectance and the consequent protection of skin.
2002-02
A new model using liposomes that allow to distinguish between absorption and oxidative properties of sunscreens.
2002-01
Photochemical studies of 4-tert-butyl-4'-methoxydibenzoylmethane (BM-DBM).
2001-11-15
Multiple chemical sensitivities, including iatrogenic allergic contact dermatitis, in a patient with chronic actinic dermatitis: implications for management.
1996-09
Patents

Patents

JP2004099889A
1
JP2005239667A
3
JP2007182387A
1
JP2007182389A
1
JP2007261978A
2
JP2008162988A
1
JP2011506741A
5
JP4833491B2
3
JPH08217621A
2
JPH09227350A
1
JPS61215316A
1

Sample Use Guides

In Vivo Use Guide
apply liberally 15 min before sun exposure. reapply as needed or after towel drying, 40 min of swimming, or perspiring.
Route of Administration: Topical
In Vitro Use Guide
Sources: DOI: 10.7324/JAPS.2015.50611
Avobenzone 2% and ethyl ascorbic acid2% represented the best photostability with avobenzone concentrations decrease by 11,82% for 15 hour using UVA lamp irradiation 4,7 mW/cm2.
Name Type Language
BUTYL METHOXYDIBENZOYLMETHANE
INCI  
INCI  
Preferred Name English
AVOBENZONE
HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
NEOHELIOPAN 357
Brand Name English
AVOBENZONE [USP-RS]
Common Name English
Avobenzone [WHO-DD]
Common Name English
NSC-758680
Code English
1,3-PROPANEDIONE, 1-(4-(1,1-DIMETHYLETHYL)PHENYL)-3-(4-METHOXYPHENYL)-
Systematic Name English
ESCALOL 517
Brand Name English
4-METHOXY-4'-TERT-BUTYLDIBENZOYLMETHANE
Common Name English
1-(4-TERT-BUTYLPHENYL)-3-(4-METHOXYPHENYL)PROPAN-1,3-DIONE
Systematic Name English
AVOBENZONE [MART.]
Common Name English
AVOBENZONE [USP IMPURITY]
Common Name English
AVOBENZONE [MI]
Common Name English
AVOBENZONE [HSDB]
Common Name English
CAPITAL SOLEIL COMPONENT AVOBENZONE
Common Name English
ANTHELIOS SX COMPONENT AVOBENZONE
Common Name English
avobenzone [INN]
Common Name English
EUSOLEX 9020
Brand Name English
AVOBENZONE [ORANGE BOOK]
Common Name English
AVOBENZONE [USP MONOGRAPH]
Common Name English
AVOBENZONE [USAN]
Common Name English
PARSOL 1789
Brand Name English
SHADE UVAGUARD COMPONENT AVOBENZONE
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 142401
Created by admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
NCI_THESAURUS C851
Created by admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
CFR 21 CFR 352.10
Created by admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
Code System Code Type Description
EVMPD
SUB05617MIG
Created by admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
PRIMARY
RXCUI
45045
Created by admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
PRIMARY RxNorm
USAN
AA-89
Created by admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
PRIMARY
WIKIPEDIA
AVOBENZONE
Created by admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
PRIMARY
INN
6480
Created by admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
PRIMARY
FDA UNII
G63QQF2NOX
Created by admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
PRIMARY
PUBCHEM
51040
Created by admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
PRIMARY
ChEMBL
CHEMBL1200522
Created by admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
PRIMARY
EPA CompTox
DTXSID9044829
Created by admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
PRIMARY
HSDB
7423
Created by admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
PRIMARY
DAILYMED
G63QQF2NOX
Created by admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
PRIMARY
ECHA (EC/EINECS)
274-581-6
Created by admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
PRIMARY
MERCK INDEX
m2151
Created by admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
PRIMARY Merck Index
RS_ITEM_NUM
1045337
Created by admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
PRIMARY
NCI_THESAURUS
C47406
Created by admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
PRIMARY
NSC
758680
Created by admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
PRIMARY
DRUG CENTRAL
4242
Created by admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
PRIMARY
CAS
70356-09-1
Created by admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
PRIMARY
DRUG BANK
DB09495
Created by admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
PRIMARY
SMS_ID
100000086882
Created by admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
PRIMARY
ACTIVE MOIETY
Structure of AVOBENZONE
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966